---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-25-000058"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:53:39.962645+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M

## Summary
- Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.
- Operating loss improved to $32.2M from $41.5M; net loss $27.5M vs $35.8M.
- Cash and marketable securities $482.1M, up $35M sequentially.
- Q4 2025 revenue guidance $154-158M (midpoint 6% decline YoY, 5% sequential growth).
- Launched next-gen Chromium Flex and Xenium Protein spatial multiomic workflow.

## SEC filing metadata
- accession: 0001770787-25-000058
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000058/0001770787-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000058/txg-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-25-000058
- JSON: https://secwatch.observer/filing/0001770787-25-000058.json
- Plain text: https://secwatch.observer/filing/0001770787-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.